Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITI-1284 in Generalized Anxiety Disorder
NCT06701903Phase 2Recruiting
- Sponsor
- Intra-Cellular Therapies
- Start
- Nov 2024
- Primary completion
- Oct 2027
- Countries
- 5
01
Overview
A Phase 2 trial of deulumateperone in generalized anxiety disorder (GAD), sponsored by Intra-Cellular Therapies. Started Nov 2024; status: recruiting.
02
Drugs
deulumateperone
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT06701903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06701903.